Phone: 614/488-2118
Fax: 614/488-2647

1335 Dublin Rd., Suite 124A
Columbus, OH 43215

Protocol Categories

View All Protocols


Hematology

Alliance A041702
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
ECOG EAA171
Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
ECOG EAA173
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
ECOG EAA181
Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
ECOG NHLBI-MDS
The National Myelodysplastic Syndromes (MDS) Study
NCI COVID-19
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
OSU 2010-C0126 Buckeye Surveillance
Buckeye Surveillance, Contact, and Research for MGUS, Myeloma and Amyloidosis
SWOG S1712
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
SWOG S1803
Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)
SWOG S1925
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study